Organogenesis Holdings Inc. (ORGO): Cash & Equivalents
$93.68M
As of 2025-12-31
$46.10M
As of 2026-06-30
-2.9%
3-year compound annual growth
+2.1%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $93.68M | -30.9% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $135.57M | +30.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $103.84M | +1.3% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $102.48M | -10.1% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $113.93M | +35.0% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $84.39M | n/a | 2022-03-01, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $93.68M | -30.9% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $71.33M | -53.7% |
| Insmed Inc (INSM) | 2025-12-31 | $510.44M | -8.0% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $364.41M | -14.6% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $296.68M | +33.3% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $79.15M | -56.0% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $570.12M | -16.3% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $322.93M | +2.4% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $93.03M | +58.9% |
Compare ORGO, HCM, INSM, OPK side by side · Screen every company in Pharmaceutical Preparations ↗